指南与共识慢阻肺

2023年加拿大胸科学会稳定期COPD药物治疗指南

2023 Canadian Thoracic Society Guideline on Pharmacotherapy in Patients With Stable COPD.
指南 / 共识 · Chest · 2023-09-09

该指南基于系统综述与Meta分析及专家意见,为稳定期COPD患者优化维持药物治疗提供推荐,并更新了2019版CTS指南的治疗路径。关键推荐包括:所有有症状且肺功能确诊的COPD患者应接受长效支气管扩张剂维持治疗;呼吸困难(mMRC≥2)和/或健康状态受损(CAT≥10)且急性加重风险低的患者应接受LAMA/LABA联合治疗;高急性加重风险者应接受三联治疗(LAMA/LABA/ICS)。

要点

  • 所有有症状且肺功能确诊的COPD患者应接受长效支气管扩张剂维持治疗。
  • mMRC≥2和/或CAT≥10且急性加重风险低者推荐LAMA/LABA联合治疗。
  • mMRC≥2和/或CAT≥10且急性加重风险高者推荐LAMA/LABA/ICS三联治疗。

核心结论

  • 所有有症状且肺功能确诊的COPD患者应接受长效支气管扩张剂维持治疗。
  • 呼吸困难(mMRC≥2)和/或健康状态受损(CAT≥10)且急性加重风险低的患者应接受LAMA/LABA联合治疗。
  • 呼吸困难(mMRC≥2)和/或健康状态受损(CAT≥10)且急性加重风险高的患者应接受LAMA/LABA/ICS三联治疗。
  • 特定人群可使用阿奇霉素、罗氟司特或N-乙酰半胱氨酸。
  • 所有COPD患者不推荐使用茶碱、维持性全身口服糖皮质激素(如泼尼松)及吸入糖皮质激素单药治疗。

研究设计与样本

  • 加拿大胸科学会(CTS)基于系统综述与Meta分析及专家临床意见制定。
  • 关键临床问题采用PICO模型构建,聚焦症状(呼吸困难)/健康状态、急性加重和死亡率三个结局。
  • 指南更新了2019版CTS指南,并提供实用的治疗路径。

主要发现

  • 系统综述与Meta分析证据支持长效支气管扩张剂作为所有有症状COPD患者的维持治疗。
  • LAMA/LABA联合治疗适用于呼吸困难(mMRC≥2)和/或健康状态受损(CAT≥10)且急性加重风险低的患者。
  • LAMA/LABA/ICS三联治疗适用于呼吸困难(mMRC≥2)和/或健康状态受损(CAT≥10)且急性加重风险高的患者。

关键数值与推荐

  • COPD诊断需通过支气管舒张后肺功能检查确认。
  • 呼吸困难采用改良医学研究委员会(mMRC)量表评估,mMRC≥2提示中重度呼吸困难。
  • 健康状态采用COPD评估测试(CAT)评估,CAT≥10提示健康状态受损。
  • 急性加重风险低者推荐LAMA/LABA,高者推荐LAMA/LABA/ICS。
  • 特定人群可使用阿奇霉素、罗氟司特或N-乙酰半胱氨酸;不推荐茶碱、维持性口服糖皮质激素及ICS单药治疗。

临床怎么用

  • 临床应通过支气管舒张后肺功能检查确认COPD诊断。
  • 全面评估患者症状负担(mMRC、CAT)和急性加重风险以指导药物选择。
  • 根据呼吸困难程度、健康状态受损及急性加重风险分层,选择长效支气管扩张剂单药、LAMA/LABA或LAMA/LABA/ICS。
  • 避免使用茶碱、维持性口服糖皮质激素及吸入糖皮质激素单药治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chronic obstructive pulmonary disease patient care must include confirming a diagnosis with postbronchodilator spirometry. Because of the clinical heterogeneity and the reality that airflow obstruction assessed by spirometry only partially reflects disease severity, a thorough clinical evaluation of the patient should include assessment of symptom burden and risk of exacerbations that permits the implementation of evidence-informed pharmacologic and nonpharmacologic interventions. This guideline provides recommendations from a comprehensive systematic review with a meta-analysis and expert-informed clinical remarks to optimize maintenance pharmacologic therapy for individuals with stable COPD, and a revised and practical treatment pathway based on new evidence since the 2019 update of the Canadian Thoracic Society (CTS) Guideline. The key clinical questions were developed using the Patients/Population (P), Intervention(s) (I), Comparison/Comparator (C), and Outcome (O) model for three questions that focuses on the outcomes of symptoms (dyspnea)/health status, acute exacerbations, and mortality. The evidence from this systematic review and meta-analysis leads to the recommendation that all symptomatic patients with spirometry-confirmed COPD should receive long-acting bronchodilator maintenance therapy. Those with moderate to severe dyspnea (modified Medical Research Council ≥ 2) and/or impaired health status (COPD Assessment Test ≥ 10) and a low risk of exacerbations should receive combination therapy with a long-acting muscarinic antagonist/long-acting ẞ2-agonist (LAMA/LABA). For those with a moderate/severe dyspnea and/or impaired health status and a high risk of exacerbations should be prescribed triple combination therapy (LAMA/LABA/inhaled corticosteroids) azithromycin, roflumilast or N-acetylcysteine is recommended for specific populations; a recommendation against the use of theophylline, maintenance systemic oral corticosteroids such as prednisone and inhaled corticosteroid monotherapy is made for all COPD patients.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Bourbeau, Bhutani, Hernandez, et al. 2023 Canadian Thoracic Society Guideline on Pharmacotherapy in Patients With Stable COPD. Chest. 2023. PMID: 37690008. doi:10.1016/j.chest.2023.08.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。